110 likes | 214 Views
”We aim to be the preferred life sciences investment company in Northern Europe…” “We have the people, the differentiation, the mind-set, and the structure to deliver better investment returns…” . Vanadis Capital unique offer: .
E N D
”We aim to be the preferred life sciences investment company in Northern Europe…”“We have the people, the differentiation, the mind-set, and the structure to deliver better investment returns…”
Vanadis Capitalunique offer: • Partnership with TFS International, the largest private and independent clinical research organization (CRO) in Europe • Team experience and background is aligned with business demands, fund management, and exit opportunities • Small size fund by design and strongly committed GP • Already screened and identified investment opportunities to bring momentum to the investment cycle right after first close
Complementary, unique, and differentiated deal flow from exclusive TFS partnership • 400+ potential target companies across Europe • Pre-validate by TFS management according to Vanadis Capital investment criteria • 40% within the Nordic region • 50% are either medtech, diagnostics, or medical services companies
“Getting the right mix of people in the team is a determinant factor to our future success as a venture firm, our competences and capabilities all put together contribute to what makes Vanadis Capital very unique and well set to deliver strong returns”
A smaller fund is advantageous compared to larger funds: • Better alignment between the GP and LP incentives • Better leverage on specialized industry expertise • Opportunity to complement larger funds at good financial conditions • Needs fewer home runs to secure high fund returns Source: Silicon Valley Bank, VC reportmay 2010
Vanadis Capital partners are strongly committed and aligned with LP incentives • GP commitment @ 6% of the fund • Cap on management fees with a focus to operate with predictable fixed costs • Transparency on GP budget • Readiness to offer deal on carries provided that GP incentives remain solid
Vanadis value creation summary • Accelerate product development • Accelerate product adoption • Strategic and operational expertise • Management reviews (including staffing) • Well prepared and executed exits
Conclusion Vanadis Capital has access to a unique pre-validated and differentiated deal flow Vanadis Capital team is competent, experienced, and strongly committed Vanadis Capital has a unique opportunity to create value in life sciences for the benefit of patients, society, and its investors!